Sunesis Pharmaceuticals, Inc.
| Nasdaq: SNSS
Sunesis Pharmaceuticals, Inc. operates as a biopharmaceutical company. The company primarily engages in development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. Its efforts are currently focused primarily on the development of vosaroxin for the treatment of acute myeloid leukemia. The company's primary activities include conducting research and development internally and through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting clinical trials and raising capital. Sunesis Pharmaceuticals was founded on February 10, 1998 and is headquartered in South San Francisco, CA.